Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

NCT07753148 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Clonal Cytopenia of Undetermined Significance (CCUS)
Low-Risk Myelodysplastic Syndrome (LR-MDS)

Interventions

DRUG: REGN17235

Sponsor

Regeneron Pharmaceuticals